New pill could shrink spleen and lymph nodes in rare ALPS disease

NCT ID NCT06730126

Recruiting now Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study tests a drug called soquelitinib in 15 people aged 16 and older with autoimmune lymphoproliferative syndrome (ALPS). The goal is to see if the drug can shrink an enlarged spleen or lymph nodes and improve low blood cell counts. Participants take the pill twice daily for up to a year, with regular blood tests and scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune lymphoproliferative syndrome Autoimmune Lymphoproliferative Syndrome, Type IA FAS-related autoimmune lymphoproliferative syndrome hypersplenism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States
Texas Children's Hospital
RECRUITING

Houston, Texas, 77030, United States
The Children's Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.